JP Morgan Maintains Overweight on Anterix, Raises Price Target to $61
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Philip Cusick maintains an Overweight rating on Anterix (NASDAQ:ATEX) and raises the price target from $60 to $61.
August 08, 2024 | 3:36 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
JP Morgan analyst Philip Cusick maintains an Overweight rating on Anterix and raises the price target from $60 to $61.
The Overweight rating and increased price target from a reputable analyst at JP Morgan is likely to positively influence investor sentiment and drive short-term price appreciation for Anterix.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100